tbuckley/cabot-search huggingface dataset:
Lancisi’s Sign
Authors: André M Mansoor, Steven E Mansoor
Journal: New England Journal of Medicine (2016)

A 60-year-old man presented with progressive dyspnea and weight gain. A holosystolic murmur that augmented with inspiration was noted at the left lower sternal border. Examination of the neck revealed a palpable, monomorphic venous pulsation, known as Lancisi's sign, shown in a video.
Interaction between Family History of Breast Cancer and the Remaining Gail Risk Factors.
Authors: X. Ni, D. Muram
Journal: Cancer Research (2009)

Abstract Background: The Gail breast cancer risk assessment model takes into account the relative contribution of various breast cancer risk factors (RF) and provides 5-year and lifetime breast cancer risk estimates. The purpose of this analysis was to determine the relative contribution of the Gail model RF in patients with and without family history of breast cancer (FHBC).Materials and Methods: Patients from the RUTH trial, consisting of postmenopausal women with or at high risk for coronary artery disease (CAD), were included in this analysis, with the exception of women ≥86 years of age or with medical history of any breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ. Patients with missing values for RF were also excluded. For the resulting study population (N=10015), the risk score was calculated using the breast cancer risk assessment (BCRA) tool from the National Cancer Institute. A descriptive analysis of the BCRA risk scores for each RF stratified based on the presence or absence of a FHBC was performed. Risk factors were categorized as follows: advancing age (&amp;lt;65 or ≥65; 65 was the mean age); age at menarche (&amp;gt;12 or ≤12), number of biopsies (None or ≥1), age at first live child birth (&amp;lt;30 or ≥30; nulliparty included in &amp;lt;30 group per model). Interaction plots based on the two-way analysis of variance (ANOVA) model were generated for each category of the RF.Results: Of the 10015 women, 9123 (91.1%) did not have FHBC, while 892 (8.9%) did. Among women without FHBC, the mean BCRA score (%) was 1.54±0.40; 62.2% were 65 years or older, 28.8% had early menarche, 8.4% had first child at ≥30 years of age, and 8.1% had a previous breast biopsy. Among women with FHBC, mean BCRA score was 3.46±1.24; 70.3% were 65 years or older, 30.4% had early menarche, 9.3% had first child at ≥30 years of age, and 15.4 % had a previous breast biopsy. A statistically significant (p&amp;lt;0.001) amplification in the risk conferred by advancing age, previous biopsy, and early menarche was observed in patients with FHBC compared with patients with no family history for the disease (Figure 1). In contrast, the relative contribution to risk by late childbearing is more pronounced (p&amp;lt;0.001) in patients without FHBC.Discussion: Family history is an independent and important determinant of breast cancer risk in postmenopausal women. Other RF have a different influence on the overall risk estimate in women with FHBC when compared to women without FHBC. Increased risk was observed for advancing age, early menarche, and previous breast biopsy. A different pattern was seen for late childbearing. While the data were obtained from a large cohort of women, further analysis may be required to determine if these results are generalizable for all women regardless of menopausal status or CAD.Figure 1. Mean BCRA risk within each risk factor group, stratified by FHBC. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6062.
473 ASSOCIATION OF VITAMIN D SERUM LEVELS AND ITS COMMON GENETIC DETERMINANTS, WITH SEVERITY OF LIVER FIBROSIS IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS
Authors: S. Petta, S. Grimaudo, V. Di Marco, C. Scazzone, F.S. Macaluso, C. Cammà, D. Cabibi, R.M. Pipitone, A. Craxi
Journal: Journal of Hepatology (2013)
A Prospective Randomized Phase Iii Study of Palliative Chemotherapy Versus Best Supportive Care in Elderly Patients with Advanced Non-Small Cell Lung Cancer: Survival Analysis and Ecog Performance Status Regression Analysis
Authors: N. Kumar, A. Kapoor, A. Kalwar, S. Narayan, M.K. Singhal, A. Kumar, S. Lal, R.K. Nirban, M. Paramanandhan, R. Purohit
Journal: Annals of Oncology (2015)
Post-treatment, Long-term Efficacy Of A 300IR Sublingual Tablet Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis: The Relationship With Disease Severity
Authors: M. Worm, A. Didier, F. Horak, H. Malling, S. Soulie, R.K. Zeldin
Journal: Journal of Allergy and Clinical Immunology (2012)
Abstract 1955: Bone-marrow-derived cells incorporate into the prostate during regrowth
Authors: Veronica R. Placencio, Taylor P. Sherrill, Xiuping Yu, Neil A. Bhowmick
Journal: Cancer Research (2010)

Abstract It is necessary to understand mechanisms of castrate resistant prostate cancer development and progression. As prostate cancer transitions from androgen dependent to castrate resistant, subsequent recurrence involves increased growth of the cancer epithelial cells. Understanding prostate regrowth in a normal prostate will allow us to better understand growth in castrate resistant prostate cancer. We hypothesized that altered chemokine signaling which accompanies the loss and subsequent return of androgen signaling results in the recruitment of immune cells to the prostate microenvironment from the bone marrow. A chimeric mouse model with GFP-labeled bone marrow was used to allow us to identify bone marrow cells recruited to the prostate. We studied how bone marrow derived cells (BMDCs) contributed to an androgen refractory response, specifically prostate regrowth. In a similar mouse model we used GFP-labeled mesenchymal stem cells (MSCs) to study this specific subset of BMDCs in response to prostate regrowth. Host mice were castrated or left intact as a control. Testosterone was given to the chimeric mice. The intact and castrated control mice had a low number of BMDCs recruited to the prostate. However, three and seven days following exogenous testosterone administration resulted in a dramatic increase in BMDC recruitment during prostate regrowth. GFP labeled MSC cells were also recruited to the prostate at three days following treatment with exogenous testosterone. Interestingly, even after four weeks the fully regrown prostates retained BMDCs that appeared to be incorporated in the epithelial compartment. Double immunofluorescence staining showed that a subset of BMDCs gained the expression of androgen receptor; p63, a basal epithelial marker; and cytokeratin 8, a luminal epithelial marker, in the prostate. Rosa26 expressing MSCs injected into GFP mice showed prostate co-localization of ß-galactosidase and GFP, suggesting that MSCs fused with resident prostate epithelial cells during regrowth. The recruitment and eventual incorporation of BMDCs in the prostate suggests a mechanism for exogenous cells in castration-resistant prostate cancer growth. This result has implications for castrate-resistant prostate cancer growth, as it too may be a result of MSC recruitment, incorporation, and fusion. NIH grants F31 GM079879 (VRP), CA108646 and CA126505 (NAB). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1955.
AB0285 Correlation between serum levels of parathyroid hormone and DICKKOPF-1 in patients with rheumatoid arthritis
Authors: G. Orsolini, M.R. Povino, G. Tripi, C. Caimmi, I. Lippolis, L. Idolazzi, E. Fracassi, O. Viapiana, D. Gatti, M. Rossini, S. Adami
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> It was recently observed that Dickkopf-1 (DKK-1), a natural inhibitor of Wnt signaling and bone formation, is correlated with inflammation and bone erosion in Rheumatoid Arthritis (RA) (1). We also observed that the presence of bone erosions in RA correlates with high serum Parathyroid Hormone (PTH) (2) and that the long-term treatment with PTH increases DKK-1 serum levels (3). <h3>Objectives</h3> Objective of this study is to explore the correlation between PTH and DKK-1 serum levels in patients with RA. <h3>Methods</h3> In serum samples from 154 patients with RA and 107 healthy controls DKK-1, 25OH vitamin D (25OHD) and PTH levels were measured by ELISA. Clinical measurements of RA disease activity included the Italian version of the Health Assessment Questionnaire Disability Index (HAQ), the Disease Activity Score 28-joint count (DAS28) and the van der Heijde modification of the Sharp erosion score. <h3>Results</h3> The two groups were not significantly different for age, body mass index and 25OHD serum levels. The mean serum level of DKK-1 was significantly higher in patients with RA than in healthy controls (172 vs 90 pmoL/L, respectively; p=0,0001). Patients with erosions had serum levels of DKK-1 slightly higher than those without erosions (179 vs 160 pmoL/L, respectively; p=0,08). The serum DKK-1 levels were significantly correlated with HAQ, DAS28 and the disease duration. Mean serum levels of PTH in RA patients were 40% higher than in controls (30 vs 22 pg/ml, respectively; p=0,0001) and were significantly correlated with DKK-1 serum levels (p&lt;0,0001). <h3>Conclusions</h3> In patients with RA serum PTH and DKK-1 are significantly increased, correlated each other and account for joint bone destruction. <h3>References</h3> Wang et al, J Rheumatol. 2011;38:821-7. Rossini et al, J Rheumatol. 2011,38:997-2002. Gatti et al, J Clin Endocrinol Metab. 2011,96:1555-9. <h3>Disclosure of Interest</h3> None Declared
Prediction of chemotherapy response in breast cancer by using a four-gene panel including osteopontin, activating leukocyte cell adhesion molecule (ALCAM), HER2 and estrogen receptor (ER).
Authors: M Ihnen, V Müller, RM Wirtz, K Milde-Langosch, I Witzel, BW Lisboa, F Jänicke
Journal: Cancer Research (2009)

Abstract Abstract #2033 Background: Several prognostic factors such as TNM-stage, hormone receptor and HER2 status refer to therapeutical decisions towards adjuvant chemotherapy. Up to now it is still difficult to predict the response to chemotherapy for a single patient, which is a challenging problem in order to spare patients from cost-intensive ineffective treatment and adverse side effects. Therefore there is urgent need for additional predictive markers. Our previous findings implicated that tumor tissue expression of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) is associated with chemotherapy response. Osteopontin (OPN) has been described as prognostic marker in breast cancer and recently it was shown that high OPN levels in vitro mediate chemoresistance of breast cancer cells by inhibition of apoptosis. If these findings result in chemoresistance in vivo has not been investigated so far. Material and Methods: Primary breast cancer tissues from 100 patients treated with Taxane-free adjuvant standard chemotherapy regimen were collected at surgery prior to any additional therapy. The median follow-up time was 81 months. We analyzed ALCAM and OPN mRNA expression in the biological context of additional and predefined breast cancer markers, like estrogen receptor (ER), Her-2/neu (HER2), members of the urokinase plasminogen activator (uPA) system, vascular endothelial growth factor (VEGF) using oligonucleotide microarrays (Affymetrix HG-U133A). Hierarchical cluster analysis was performed to develop a gene algorithm predicting outcome after standard chemotherapy. Results: In contrast to ALCAM overexpression, which was associated with better outcome upon chemotherapy, OPN overexpression was associated with a significantly higher recurrence rate (p=0,027), but not with shorter overall survival. In addition, there were significant positive correlations of OPN with uPA, PAI-1, uPAR and VEGF-A mRNA expression. By cluster analysis based on the four markers ER, HER2, ALCAM and OPN, we identified a group of high-risk patients, which was characterized by low ER and HER2 expression, high OPN and low ALCAM levels, and with significantly shorter recurrence-free and overall survival (p&amp;lt;0,001). Discussion: In our cohort of patients the combination of ALCAM, OPN, ER and HER2 expression levels turned out as valuable predictive marker for response to adjuvant Taxane-free chemotherapy. The ratio of high OPN and low ALCAM levels was particularly associated with chemoresistance and a poor prognosis in tumors having low ER and HER2 expression levels. We hypothesize that this simple four-gene panel could help to reassign an optimized therapy to the single patients. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2033.
P0460 : CD3hiCD4- Vγ9/Vδ2 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B
Authors: J.-J. Park, D. Traum, S. Ho, A.S. Wahed, G. Johnson, K. Ojiro, D.K. Wong, W.M. Lee, N. Terrault, M. Khalili, R.K. Sterling, K.V. Kowdley, D.T. Lau, L.R. Roberts, C. Smith, R.L. Carithers, D.L. Levine, J. Keith, M.E. Valiga, M. Betts, H. Janssen, A.S.F. Lok, K.-M. Chang
Journal: Journal of Hepatology (2015)
Abstract LB-97: Aurora kinase inhibition suppresses colon cancer cell growth through NF-κb-mediated PUMA induction.
Authors: Jing Sun, Kan He, Jian Yu, Lin Zhang
Journal: Cancer Research (2013)

Abstract Aurora kinases are a group of highly conserved protein kinases that play a key role in mitosis. It has been shown that aurora kinases are overexpressed in a variety of tumors, and their overexpression contributes to aneuploidy in cancer cells. Inhibitors of aurora kinases have been developed and showed promises in recent studies. However, the mechanisms by which aurora kinase inhibitors suppress tumor cell growth have remained unclear. In this study, we found that ZM-447439, an aurora B inhibitor that has been tested in a number of preclinical studies, suppressed colon cancer cell growth by inducing apoptosis through PUMA, a p53 downstream target and a BH3-only Bcl-2 family protein. Treatment with ZM-447439 strongly induced PUMA in a variety of colon cancer cells irrespective of their p53 status. The induction of PUMA by ZM-447439 is mediated by IκB-dependent activation of NF-κB, which directly binds to the PUMA promoter to activate its transcription. Deficiency in PUMA abrogated ZM-447439-induced apoptosis and caspase activation, and rendered ZM-447439 resistance in vitro and in vivo. Furthermore, chemosensitization by ZM-447439 was also found to be PUMA-dependent. Together, these results demonstrate a key role of PUMA-dependent apoptosis in mediating the therapeutic effect of aurora kinase inhibition. They provide a rationale for manipulating the apoptotic machinery to improve sensitivity and overcome resistance to aurora kinase inhibitors. Citation Format: Jing Sun, Kan He, Jian Yu, Lin Zhang. Aurora kinase inhibition suppresses colon cancer cell growth through NF-κb-mediated PUMA induction. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-97. doi:10.1158/1538-7445.AM2013-LB-97
Interventional EUS as an alternative to endoscopic biliary decompression through the duodenal papilla is feasible and safe
Authors: Tsutsumi Koichiro, Kawamoto Hirofumi, Noma Kazuhiro, Sonoyama Takayuki, Fujii Masakuni, Kato Hironari, Kurihara Naoko, Okada Hiroyuki, Yamamoto Kazuhide
Journal: Endoscopy (2011)

Background and aim: EUS-guided biliary drainage (EUS-BD) has been developed as an alternative drainage procedure in patients with obstructive jaundice when endoscopic biliary drainage (EBD) failed. In addition, EUS-guided gallbladder drainage (EUS-GBD) has been employed as a new procedure which replaces percutaneous transhepatic gallbladder drainage in patients with cholecystitis. We evaluated the feasibility and safety of these procedures.
ESTIMATION OF ACUTE ONSET GLOBAL LONGITUDINAL STRAIN BY 3D SPECKLE TRACKING AFTER ST-ELEVATION MYOCARDIAL INFARCTION IS USEFUL FOR PREDICTION OF FINAL INFARCT SIZE AND LEFT VENTRICULAR REMODELING
Authors: Noriaki Iwahashi, Masaomi Gohbara, Eiichi Akiyama, Shunsuke Kataoka, Nobuhiko Maejima, Kengo Tsukahara, Kiyoshi Hibi, Masami Kosuge, Toshiaki Ebina, Satoshi Umemura, Kazuo Kimura
Journal: Journal of the American College of Cardiology (2015)
FRI0034 Functional DRB1 Shared Epitope Subtypes Correlate with Joint Damage in Latin American Rheumatoid Arthitis Patients:
Authors: R.V. Gamboa-Cardenas, C. Sanchez-Zuñiga, M.F. Ugarte-Gil, A. Mosqueira-Riveros, F. Zevallos, M. Aliaga-Zamudio, M. Medina, J.L. Alfaro-Lozano, Z. Rodriguez-Bellido, J.M. Cucho-Venegas, R.A. Perich-Campos, C.A. Pastor-Asurza
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> New Classifications of HLADRB1 alleles expanding the concept of the Shared Epitope (SE) hypothesis have allowed to profile predisposing or protective determinants of aggressive disease course in Caucasian patients with Rheumatoid Arthritis (RA). In mestizo Latin American (LA) subjects there is scarce information available. <h3>Objectives</h3> To determine if SE subtypes according to Gao classification are associated with risk of more severe joint damage in a RA LA cohort <h3>Methods</h3> A cross sectional study was conducted in RA outpatients between September to December 2013. HLA–DRB1 typification was performed by a polymerase chain reaction–based method, using a panel of sequence-specific oligonucleotides. DRB1 subtyping was described according to the classification of HLA DRB1 alleles by Gao et al: E<sub>1</sub>, E<sub>3</sub> (QRRAA), E<sub>2</sub>/E<sub>x</sub> (KRAA), E<sub>x</sub> (ERAA) or Ex (DERAA). Then four categories were pre determined: I = none present (0/0); II = E<sub>1</sub>,E<sub>3</sub> (+/0 or +/+), III = E<sub>1</sub>, E<sub>3</sub>, E<sub>x</sub>(+/+), and IV= E<sub>x</sub> (+/0 or +/+). A single blind investigator (RG) determined Joint Damage according to erosion, narrowing and total Sharp Van Der Heijde (Sharp VDH) score. Other severity risk factors were measured. A univariable Student9s t test to compare all categories was done. Then a regression multivariable linear analysis was performed to determine the association of these DRB1 categories with joint damage adjusted to other risk factors. All analyses were performed using SPSS 21.0. <h3>Results</h3> One hundred and seventy nine patients were included, 90.5% (162) were women, media of age was 58.9 (12.87) years, Disease duration 15.84 (11.76) years and 31 patients (17.3%) had tobacco habits in the past. The total, erosion and narrowing space Sharp VDH score were 110.33 (86.36), 41.85 (48.45) and 68.48 (41.26) respectively, DAS28 was 4.69 (1.26), MDHAQ was 0.88 (0.60) and Charlson index 0.65 (1.27). On univariate analysis Category II was associated to Sharp VDH score (Table 1) After the multivariable analyses (adjusted for age, disease duration, gender, tobacco, Rheumatoid Factor, DAS28 and Charlson comorbidity index) category II persisted associated with erosions (B: 29.32; IC 95%: 1.19-57.44, p=0.041), and total (B: 50.52; IC 95%: 2.59-98.45, p=0.039) Sharp VDH index but not with narrowing score (B: 21.20; IC 95%: -1.02-43.42, p=0.061) <h3>Conclusions</h3> Presence of HDRB1 E<sub>1</sub> and/or E<sub>3</sub> alleles are independently associated with structural severity on our RA Peruvian patients. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5660
Effect of Lung-Volume–Reduction Surgery in Patients with Severe Emphysema
Authors: Duncan Geddes, Michael Davies, Hiroshi Koyama, David Hansell, Ugo Pastorino, John Pepper, Penny Agent, Paul Cullinan, Stephanie J. MacNeill, Peter Goldstraw
Journal: New England Journal of Medicine (2000)

Although many patients with severe emphysema have undergone lung-volume–reduction surgery, the benefits are uncertain. We conducted a randomized, controlled trial of the surgery in patients with emphysema. Patients with isolated bullae were excluded because such patients are known to improve after bullectomy.
Detecting circulating tumor cells in metastatic breast cancer patients using fiber-optic array scanning technology
Authors: D. Marrinucci, K. Bethel, N. Lazarus, M. Leach, J. Kroener, R. Bruce, P. Kuhn, J. Nieva
Journal: Journal of Clinical Oncology (2007)

1022 Background: Circulating tumor cell (CTC) detection and enumeration has been shown to be a valuable tool for determining prognosis in metastatic breast cancer patients. CTCs are rare, existing in the circulation at estimated concentrations of 1 in 1 - 10 million normal blood cells. To date, the most widely used technique to detect CTCs has used immunomagnetic enrichment based protocols. In this validation study, we sought to determine if an enrichment free approach using an immunofluorescent cell attachment protocol along with fiber-optic array scanning technology (FAST) could achieve similar results. Methods: We have developed and validated a scanning instrument using FAST that can be used in conjunction with an immunofluorescence staining protocol to efficiently detect CTCs. The protocol uses a pan anti-cytokeratin antibody cocktail directed against 9 cytokeratins along with a DAPI nuclear counterstain. FAST defines cell positions, so relocation and retrospective analysis of CTCs is possible. Using this system, we assayed 50 blood specimens obtained from metastatic breast cancer patients. Pathologic review of CTCs was performed identifying CTCs as cytokeratin positive and DAPI positive. Survival analyses were determined using Kaplan-Meier analyses. Results: 31 women with metastatic breast cancer were enrolled in the study and provided 50 peripheral blood specimens. The median CTC count for patients with progressive disease was 8.5, while the median CTC count for patients with stable or responding disease was 1. At a median follow-up of 1 year, 11 patients had died. Patients with =5 CTCs had a median survival of 212 days, while the median survival for patients with 0–4 CTCs had not been reached after 1 year (p=0.0012). Patients with progressive disease had significantly higher CTC counts (p&lt;0.0001) than those who were stable or responding to therapy. Conclusions: This study confirms the previously reported efficacy of CTC enumeration in determining the prognosis of metastatic breast cancer patients and establishes the potential utility of the FAST cytometer as a method for CTC enumeration. No significant financial relationships to disclose.
TEMPORAL TRENDS AND CLINICAL CORRELATES OF ICD IMPLANTATION AMONGST PATIENTS ACTIVELY LISTED FOR HEART TRANSPLANTATION
Authors: Kairav Vakil, Kashan S. Abidi, M Chadi Alraies, Sue Duval, Monica Colvin-Adams, Ziad Taimeh, Selcuk Adabag
Journal: Journal of the American College of Cardiology (2015)